William Blair research analyst Matt Phipps was quoted by CNBC in its coverage of targeted radiopharmaceutical therapy, a new approach to cancer treatment that is drawing the attention of major players in the biopharmaceutical sector.
Phipps, whose coverage includes Bristol Myers Squibb, a company that has shown interest in acquisition of a provider of the technology, said it is showing “urgency” for the solution, especially as several of its patents are set to expire over the coming years.